In support of the second scenario, we recently discovered that the depletion or inhibition of USP10 in TP53-null or TP53-mutant non-small cell lung cancer (NSCLC) reduces tumor burden in a xenograft mouse model and sensitizes tumors to cisplatin, highlighting USP10’s chemo-resistant role in this subset of NSCLC. Here, TP53 is linked to non-small cell lung carcinoma.